1-azido-2-phenyl-2-(N-tert-butoxycarbonylamino)ethane | 138457-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-azido-2-phenyl-2-(N-tert-butoxycarbonylamino)ethane
• 英文别名: tert-butyl 2-azido-1-phenylethylcarbamate；tert-butyl N-(2-azido-1-phenylethyl)carbamate
• CAS: 138457-47-3
• 化学式: C₁₃H₁₈N₄O₂
• 分子量: 262.312
• InChiKey: DIFATXRZXSUITE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  52.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-azido-2-phenyl-2-(N-tert-butoxycarbonylamino)ethane 在 palladium on activated charcoal 氯仿 、 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以76%的产率得到1-(N-tert-butoxycarbonyl)-2-phenyl-1,2-diaminoethane hydrochloride
  参考文献：
  名称：

  Synthesis of 1,2-aminoazides. Conversion to unsymmetrical vicinal diamines by catalytic hydrogenation or reductive alkylation with dichloroboranes.

  摘要：

  1,2-aminoazides are easily prepared from 1,2-amino alcohols. Catalytic hydrogenation in the presence of palladium on charcoal or reductive alkylation with dichloroboranes afford with good yields unsymmetrically substituted vicinal diamines.

  DOI：

  10.1016/s0040-4020(01)91013-0
• 作为产物：
  描述：

  tert-butyl 2-hydroxy-1-phenylethylcarbamate 在 三(2-氯乙基)胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 二氯甲烷 、 苯 为溶剂， 以73%的产率得到1-azido-2-phenyl-2-(N-tert-butoxycarbonylamino)ethane
  参考文献：
  名称：

  Synthesis of 1,2-aminoazides. Conversion to unsymmetrical vicinal diamines by catalytic hydrogenation or reductive alkylation with dichloroboranes.

  摘要：

  1,2-aminoazides are easily prepared from 1,2-amino alcohols. Catalytic hydrogenation in the presence of palladium on charcoal or reductive alkylation with dichloroboranes afford with good yields unsymmetrically substituted vicinal diamines.

  DOI：

  10.1016/s0040-4020(01)91013-0

文献信息

• Chemo- and Site-Selective Alkyl and Aryl Azide Reductions with Heterogeneous Nanoparticle Catalysts
  作者：Venkatareddy Udumula、S. Hadi Nazari、Scott R. Burt、Madher N. Alfindee、David J. Michaelis

  DOI：10.1021/acscatal.6b01217

  日期：2016.7.1

  to generating new leads for drug discovery. Herein, we show that heterogeneous nanoparticle catalysts enable site-selective monoreduction of polyazide substrates for the generation of aminoglycoside antibiotic derivatives. The nanoparticle catalysts are highly chemoselective for reduction of alkyl and aryl azides under mild conditions and in the presence of a variety of easily reduced functional groups

  生物活性天然产物的位点选择性修饰是产生用于药物发现的新线索的有效方法。在这里，我们表明，异质纳米颗粒催化剂能够实现聚叠氮化物底物的位点选择性单还原，以生成氨基糖苷类抗生素衍生物。纳米颗粒催化剂在温和条件下和在各种容易还原的官能团存在下对烷基和芳基叠氮化物的还原具有高度的化学选择性。已显示出用于单叠氮化物还原的高区域选择性有利于空间上受阻最小的叠氮化物的还原。我们假设观察到的选择性源自较少受阻的叠氮化物基团与纳米颗粒催化剂表面相互作用的更大能力。
• [EN] DUAL-ACTION INHIBITORS AND METHODS OF USING SAME<br/>[FR] INHIBITEURS À DOUBLE ACTION ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AERIE PHARMACEUTICALS INC

  公开号：WO2010127329A1

  公开（公告）日：2010-11-04

  Provided are compounds, compositions, and methods for treating diseases and conditions wherein an inhibitor of a kinase, such as rho kinase (ROCK), and an inhibitor of one or more of the monoamine transporters, such as NET or SERT, act in concert to improve the condition.

  提供了治疗疾病和症状的化合物、组合物和方法，其中一种激酶抑制剂（如rho激酶（ROCK））和一种或多种单胺转运体抑制剂（如NET或SERT）共同作用以改善病情。
• DERIVATIVES OF 1-(SUBSTITUTED SULFONYL)-2-AMINOIMIDAZOLINE AS ANTITUMOR AND ANTIPROLIFERATIVE AGENTS
  申请人：OncoArendi Therapeutics Sp. z o.o.

  公开号：US20140309240A1

  公开（公告）日：2014-10-16

  The invention provides novel, water-soluble 2-aminoimidazoline derivatives having general Formula (I) as well as some precursors of Formula (I), which are very potent inducers of G2/M cell cycle arrest. In treated tumor cells, compounds of Formula (I) give gene expression profile distinct from known antimitotic agents. The invention also provides methods for preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirably high levels of cell proliferation. The compounds of the invention are also expected to have utility as research tools.

  该发明提供了具有一般式（I）的新型水溶性2-氨基咪唑啉衍生物以及一些一般式（I）的前体，这些衍生物是非常有效的G2/M细胞周期阻滞诱导剂。在处理的肿瘤细胞中，一般式（I）的化合物提供了与已知抗有丝分裂剂不同的基因表达谱。该发明还提供了制备这些化合物的方法，以及使用这些化合物治疗癌症或其他由细胞过度增殖导致的哺乳动物疾病的方法。该发明的化合物还预计具有作为研究工具的用途。
• Novel ethylenediamine derivatives
  申请人：Nakamoto Yumi

  公开号：US20070129371A1

  公开（公告）日：2007-06-07

  A compound represented by the following formula (1): Q 1 —Q 2 —T o —N(R 1 )—Q 3 —N(R 2 )—T 1 —Q 4 ( 1 ) [wherein, R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or the like; Q 2 is a single bond or the like; Q 3 represents the following group: —C(R 3a )(R 4a )—C(R 3b )(R 4b )}m 1 —C(R 3c )(R 4c )}m 2 —C(R 3d )(R 4d )}m 3 —C(R 3e )(R 4e )}m 4 —C (R 3f )(R 4f )— (in which, R 3a to R 4e represent hydrogen or the like); T 0 represents a carbonyl group or the like; and T 1 represents —COCONR— or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  以下化合物公式（1）表示的化合物：Q1-Q2-To-N（R1）-Q3-N（R2）-T1-Q4（1）[其中，R1和R2是氢原子或类似物；Q1是饱和或不饱和的5或6元环烃基，可以具有取代基或类似物；Q2是单键或类似物；Q3表示以下基团：-C（R3a）（R4a）-C（R3b）（R4b）}m1-C（R3c）（R4c）}m2-C（R3d）（R4d）}m3-C（R3e）（R4e）}m4-C（R3f）（R4f）-（其中，R3a到R4e代表氢或类似物）；T0表示羰基基团或类似物；T1表示-COCONR-或类似物]；或其盐，溶剂化合物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥漫性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固。
• DUAL-ACTION INHBITORS AND METHODS OF USING SAME
  申请人：deLong Mitchell A.

  公开号：US20120135984A1

  公开（公告）日：2012-05-31

  Provided are compounds, compositions, and methods for treating diseases and conditions wherein an inhibitor of a kinase, such as rho kinase (ROCK), and an inhibitor of one or more of the monoamine transporters, such as NET or SERT, act in concert to improve the condition.

  提供了化合物、组合物和方法，用于治疗疾病和情况，其中激酶抑制剂，如rho激酶（ROCK），和一种或多种单胺转运体抑制剂，如NET或SERT，共同作用以改善病情。